Lumiradx

Lumiradx company information, Employees & Contact Information

Explore related pages

Related company profiles:

Roche Diagnostics has acquired LumiraDx's next-generation point-of-care Platform technology. This is a significant milestone, and we are excited about the next chapter, combining our knowledge and expertise to continue delivering innovative solutions for patients. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Company Details

Employees
416
Founded
-
Address
3 More London Riverside, London,london Se1 2aq,united Kingdom
Phone
44 1172 842 535
Email
en****@****x.co.uk
Industry
Hospitals And Health Care
NAICS
Health Care and Social Assistance
Social Assistance
HQ
London, London
Looking for a particular Lumiradx employee's phone or email?

Lumiradx Questions

News

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche - Yahoo Finance

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche Yahoo Finance

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System - PR Newswire

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System PR Newswire

Roche x LumiraDx: Accelerating innovation in near-patient care - Roche

Roche x LumiraDx: Accelerating innovation in near-patient care Roche

LumiraDx to sell point of care technology platform to Roche for $295M - Mobi Health News

LumiraDx to sell point of care technology platform to Roche for $295M Mobi Health News

LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp. - Business Wire

LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp. Business Wire

Akin Advises Pharmakon Funds on Sale of LumiraDx Point of Care Technology to Roche - akingump.com

Akin Advises Pharmakon Funds on Sale of LumiraDx Point of Care Technology to Roche akingump.com

LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing - BioSpace

LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing BioSpace

Roche acquires Point of Care technology from LumiraDx - Medical Device Network

Roche acquires Point of Care technology from LumiraDx Medical Device Network

Roche to buy part of LumiraDx diagnostics platform for $295 million - Reuters

Roche to buy part of LumiraDx diagnostics platform for $295 million Reuters

Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™-Antigen-detecting point-of-care device for SARS-CoV-2 - medRxiv

Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™-Antigen-detecting point-of-care device for SARS-CoV-2 medRxiv

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th - Yahoo Finance

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th Yahoo Finance

Roche to buy LumiraDx’s point-of-care technology for $295M - medtechdive.com

Roche to buy LumiraDx’s point-of-care technology for $295M medtechdive.com

LumiraDx Announces US Launch of its Rapid Onsite COVID-19 Surveillance Test - PR Newswire

LumiraDx Announces US Launch of its Rapid Onsite COVID-19 Surveillance Test PR Newswire

Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform - Business Wire

Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform Business Wire

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal - Yahoo Finance

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal Yahoo Finance

LumiraDx Reports Third Quarter 2021 Financial Results - PR Newswire

LumiraDx Reports Third Quarter 2021 Financial Results PR Newswire

LumiraDx Announces Strategic Refocus and Cost Restructuring Program - Yahoo Finance

LumiraDx Announces Strategic Refocus and Cost Restructuring Program Yahoo Finance

LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement - PR Newswire

LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement PR Newswire

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test - PR Newswire

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test PR Newswire

A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care - medRxiv

A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care medRxiv

Roche acquires LumiraDx’s point of care technology for $295m - Medical Device Network

Roche acquires LumiraDx’s point of care technology for $295m Medical Device Network

Roche to Pick Up ‘Troubled’ LumiraDx’s POC Platform Business - Medical Device and Diagnostic industry

Roche to Pick Up ‘Troubled’ LumiraDx’s POC Platform Business Medical Device and Diagnostic industry

SPAC slashes value of LumiraDx merger by $2B on falling COVID-19 testing forecast - medtechdive.com

SPAC slashes value of LumiraDx merger by $2B on falling COVID-19 testing forecast medtechdive.com

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care - GlobeNewswire

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care GlobeNewswire

Roche to pick up LumiraDx’s point-of-care tests through $350M deal - Fierce Biotech

Roche to pick up LumiraDx’s point-of-care tests through $350M deal Fierce Biotech

LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete - PR Newswire UK

LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete PR Newswire UK

Roche Completes Acquisition of LumiraDx’s Point of Care Technology - The Healthcare Technology Report.

Roche Completes Acquisition of LumiraDx’s Point of Care Technology The Healthcare Technology Report.

LumiraDx: Who we are - SelectScience

LumiraDx: Who we are SelectScience

LumiraDx receives approval for its COVID-19 Antigen Test for use in India - PR Newswire UK

LumiraDx receives approval for its COVID-19 Antigen Test for use in India PR Newswire UK

LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete - PR Newswire UK

LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete PR Newswire UK

LumiraDx launches Rapid Microfluidic Immunoassay C-Reactive Protein Test to help combat Antimicrobial Resistance in India - Business Standard

LumiraDx launches Rapid Microfluidic Immunoassay C-Reactive Protein Test to help combat Antimicrobial Resistance in India Business Standard

LumiraDx goes public as SPAC deal closes - MassDevice

LumiraDx goes public as SPAC deal closes MassDevice

LumiraDx Platform - SelectScience

LumiraDx Platform SelectScience

Point of care testing comes of age - Raconteur

Point of care testing comes of age Raconteur

LumiraDx to start trading on Nasdaq through $5B SPAC deal - MassDevice

LumiraDx to start trading on Nasdaq through $5B SPAC deal MassDevice

LumiraDx (LMDX) Stock Price, News & Analysis - MarketBeat

LumiraDx (LMDX) Stock Price, News & Analysis MarketBeat

Roche buys LumiraDx’s Point-of-Care technology for more than $300 M - BioSpectrum Asia

Roche buys LumiraDx’s Point-of-Care technology for more than $300 M BioSpectrum Asia

Biopharma Credit updates on acquisition of LumiraDx by Roche - QuotedData

Biopharma Credit updates on acquisition of LumiraDx by Roche QuotedData

LumiraDx was valued at $5bn three years ago. Now, it is shuttering its Irish subsidiary - The Currency

LumiraDx was valued at $5bn three years ago. Now, it is shuttering its Irish subsidiary The Currency

LumiraDx continues expansion of HbA1c test - Health Tech World

LumiraDx continues expansion of HbA1c test Health Tech World

LumiraDx (NASDAQ: LMDX) stock up 134% on apparently silly rumour - Dhaka Tribune

LumiraDx (NASDAQ: LMDX) stock up 134% on apparently silly rumour Dhaka Tribune

LumiraDx launches C-Reactive Protein test to combat antimicrobial resistance in India - ET HealthWorld

LumiraDx launches C-Reactive Protein test to combat antimicrobial resistance in India ET HealthWorld

LumiraDx launches POC test to help combat antimicrobial resistance in India - BioSpectrum India

LumiraDx launches POC test to help combat antimicrobial resistance in India BioSpectrum India

LumiraDX: Further job cuts loom for Clackmannanshire and Stirling workers - Alloa Advertiser

LumiraDX: Further job cuts loom for Clackmannanshire and Stirling workers Alloa Advertiser

LumiraDx bags CDSCO approval for COVID-19 antigen test - BioSpectrum India

LumiraDx bags CDSCO approval for COVID-19 antigen test BioSpectrum India

Top Lumiradx Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant